Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 0.90 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 0.90 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.90 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.90 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.90 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.90 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.90 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.90 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.90 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.90 |
| ▸ | MAPT | P10636 | 6/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.90 |
| ▸ | TSHR | P16473 | 5/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | MTOR | P42345 | 3/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL28153370 | 1.00 | KDM4E (0.90) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29374823 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL20493843 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29371663 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL2837188 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL29396039 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL11647 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL3815 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL11631789 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL29519331 | 0.95 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262173-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS OF USE | RA CAPITAL AGENCY SERVICES, LLC, AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES | 2025-08-21 | — | — | US | claimed |
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | AEGIS THERAPEUTICS, LLC (US) | 2024-03-05 | — | — | US | claimed |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | NEF ROYALTY SUB LLC | 2024-01-25 | — | — | US | claimed |
| EP-3233061-B1 | METHOD AND COMPOSITIONS FOR DISSOLVING OR SOLUBILIZING THERAPEUTIC AGENTS | WINDGAP MEDICAL INC (US) | 2022-06-01 | — | — | EP | claimed |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | claimed |
| EP-3082419-A2 | DRUG MIXING AND DELIVERY SYSTEM AND METHOD | Windgap Medical, Inc. (US) | 2016-10-26 | — | — | EP | claimed |
| CN-106061253-A | Drug mixing and delivery systems and methods | 温德加普医疗股份有限公司 | 2016-10-26 | — | — | CN | claimed |
| WO-2015095624-A2 | DRUG MIXING AND DELIVERY SYSTEM AND METHOD | WINDGAP MEDICAL, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | ALLERGAN, INC. | 2007-10-25 | — | — | US | claimed |
| US-20050282902-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | ALLERGAN, INC. | 2005-12-22 | — | — | US | claimed |
| EP-0739210-B1 | COMPOSITIONS FOR LOCAL DELIVERY OF CYTOSTATIC AGENTS | MATRIX PHARMA (US) | 2002-07-24 | — | — | EP | claimed |
| WO-2026089942-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR INTRANASAL DELIVERY OF DRY POWDER EPINEPHRINE | Belhaven BioPharma Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2002026223-A2 | CATECHOLAMINE PHARMACEUTICAL COMPOSITIONS AND METHODS | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2002-04-04 | — | — | WO | disclosed |
| EP-0349487-A2 | Antimicrobial ophthalmic solutions containing dodecyl-dimethyl-(2-phenoxyethyl)-ammonium bromide and methods of using the same | CIBA-GEIGY AG (CH) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249581-A1 | Abnormal Cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | ADRB2 31/4885ADRB1 34/4885ADRB3 53/4885 |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ADRB2 20/4885ADRB1 23/4885ADRB3 46/4885 |
| US-11918655-B2 | Intranasal epinephrine formulations and methods for the treatment of disease | ADRA2C, ADRA2A, ADRB2 | ADRB2 3/4885ADRB1 7/4885ADRB3 9/4885 |
| US-20070249731-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, PTGIR | ADRB2 31/4885ADRB1 34/4885ADRB3 53/4885 |
| US-20250262173-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS OF USE | ADRA2C, ADRA2A, ADRA2B | ADRB2 5/4885ADRB1 7/4885ADRB3 8/4885 |
| US-20070249602-A1 | 4-(1-isopropyl-4-methyl-1,2,5,6-tetra-hydropyridin-2-yl)-5-methylbenzene- 1,3-diol; glaucoma or ocular hypertension | PTGIR, PTGS1, PTGIS | ADRB2 40/4885ADRB1 25/4885ADRB3 107/4885 |
| US-20050282902-A1 | Abnormal cannabidiols as agents for lowering intraocular pressure | CNR2, CNR1, FAAH2 | ADRB2 11/4885ADRB1 25/4885ADRB3 12/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | ADRB2 183/4885ADRB1 228/4885ADRB3 219/4885 |
| US-20240024485-A1 | INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE | ADRA2C, ADRA2A, ADRB2 | ADRB2 3/4885ADRB1 7/4885ADRB3 9/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | ADRB2 20/4885ADRB1 23/4885ADRB3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.